krn330
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00575562)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cell surface A33 antigenBINDING AGENT
GPA33 binding agent
- Cell surface A33 antigenINHIBITOR
GPA33 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109293 ↗
Also known as
- krn330
- krn-330
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00838578 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2009 | Kyowa Hakko Kirin |
| NCT00575562 | Phase 1 | Jun 1, 2007 | Kyowa Hakko Kirin, SCRI Development Innovations, Vanderbilt University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyowa Hakko Kirin | For profit | 2 | 2 | 2 | 2007 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2007 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1